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of cost and resource use for both squamous and non-squamous management are 
substantial, especially considering the limited efficacy and high toxicity of existing 
treatments. Cost effectiveness of real-world treatment needs to be further explored.
PCN118
TreaTmeNT SequeNCiNg PaTTerNS aNd CoSTS of Care iN PaTieNTS wiTh 
relaPSed/refraCTory mulTiPle myeloma
Potluri R1, Farr AM2, Hirji I3, Davis C4, Bhandari H5, Oukessou A4
1SmartAnalyst Inc., New York, NY, USA, 2Truven Health Analytics, Bethesda, MD, USA, 3Bristol-
Myers Squibb, Wallingford, CT, USA, 4Bristol-Myers Squibb, Princeton, NJ, USA, 5SmartAnalyst 
India (Pvt.) Ltd., Gurgaon, India
Objectives: To evaluate treatment sequences and associated costs among 
patients with relapsed/refractory multiple myeloma (RRMM). MethOds: Patients 
with RRMM between January 2007 and September 2013 were identified from US 
MarketScan databases. Outcomes included treatment regimen per line (L; 2–4L), 
sequences of treatment regimens, and cost per line and of progression (2L vs > 2L). 
All-cause and MM-specific monthly costs captured inpatient, outpatient, emergency 
department, and drug-related costs, adjusted for censoring. Results: 4449 MM 
patients initiated a 2L regimen, of whom 38% (n= 1696) progressed to 3L and 15% 
(n= 689) progressed to 4L. Median follow-up was 14 months (range 1–83). The most 
frequent 2L regimens were lenalidomide (18%), lenalidomide-dexamethasone (12%), 
bortezomib-dexamethasone (12%), bortezomib-lenalidomide-dexamethasone (10%), 
and bortezomib (7%). Of patients whose prior therapy included an immunomodula-
tory drug (IMiD) (n= 1752), bortezomib-dexamethasone was the most common 2L 
regimen (17%); for those with no prior IMiD exposure (n= 2697), lenalidomide was 
the most common 2L (23%). Median time to start of 3L was 5.8 months. Among the 
27% of lenalidomide 2L patients who progressed to 3L, 64% had bortezomib-based 
regimens in 3L. Among the 47% of bortezomib-dexamethasone 2L patients who 
progressed to 3L, 63% had lenalidomide-based regimens in 3L. MM-specific costs 
were highest for all patients during the first year of 2L: $122,960 versus $74,573 
(12–24 mths), $68,940 (24–36 mths), $59,327 (36+ mths). Drug-related costs accounted 
for 39–62%, and were dependent on regimen and treatment line. During 0–36 mths, 
MM-specific costs after progression from 2L were higher by $122,823 compared 
with costs incurred on 2L. cOnclusiOns: In this study of RRMM patients, 38% pro-
gressed to subsequent treatment lines, with variability in 2L regimens and treatment 
sequences. Highest costs were incurred during the first 12 months of follow-up. The 
cost of managing progressive disease in RRMM is high, as observed by the difference 
in costs before and after progression.
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Objectives: The objective of this cross-sectional survey was to measure the 
resource utilisation and costs associated with health-care management of patients 
with aggressive histological types of Non-hodgkin lymphomas (a-NHLs) in Slovakia 
and to provide a basis for cost-effectiveness evaluations. The latest official national 
data on epidemiology of all NHLs are available for year 2008, prediction to 2015 
indicates the age-standardized (ASR-W) incidence to be 4.9/100,000 (n= 446 cases), 
from that DLBCL is estimated to be 311 cases (3.1/100,000). Overall point prevalence 
of all NHLs is estimated to 1,404 patients. MethOds:: Descriptive data of 1,080 
a-NHLs patients from 3 biggest NHLs-centers from whole Slovakia were collected 
and analyzed. All types of health-care services, treatment management and costs 
were analyzed. Continuous variables were calculated using standard descriptive 
statistics methods. Results: 98.97% of patients were treated by the 1st line (L), out 
of them 97.10% of patients (95%CI:97.01%-97.19%) by rituximab. Proportion of remis-
sions after 1stL represented 63.47%, deaths 6.76% and progression/relaps 29.77% 
(95%CI:29,18%-30,36%), out of them 91.99% (95%CI:91.49%-92.50%) received 2ndL 
therapy. Proportion of remissions after 2ndL was 26.48%, deaths 11.27% and pro-
gression/relaps 62.25% (95%CI:62.16%-62.34%), out of them 91.04% (95%CI:90.42%-
91.66%) received 3rdL treatment. Proportion of remissions after 3rdL represented 
7.86%, deaths 35.68%, progression/relaps 57.61% (95%CI:56.99%-58.23%), out of them 
20.45% of patients (95%CI:18.50%-22.41%) are re-treated with rituximab. Overall 
costs of patient on active treatment during therapy represented € 1,609.80/28 days 
(95%CI: € 1,571.39-€ 1,648.72), in the post-treatment time € 31.56 (95%CI:€ 29.16-€ 34.10). 
Costs of palliative care represented € 1,283.53/28 days (95%CI:€ 1,197.88-€ 1,372.94) 
and one-off costs € 405.56 (95%CI:€ 400.88-€ 410.26). Costs of adverse events man-
agement ranged in the grade 2 from € 10.58/pain (95%CI:€ 8.50-€ 11.06) to € 103.23/
fatigue (95%CI:€ 100.01-€ 106.49); in the grade 3/4 from € 111.75/lymphopenia 
(95%CI:€ 105.78-€ 117.73) to € 4,518.06/other malignant tumors (95%CI:€ 4,476.87-€ 
4,559.26). cOnclusiOns: Results of this cross-sectional survey determined the 
treatment strategies and average direct cost per a-NHL patient and can be used for 
the purposes of pharmaco-economic evaluations.
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Objectives: Recent data characterizing metastatic SCCHN treatment pat-
terns in the UK are limited. The current study evaluated patterns of care and 
HCRU in UK patients with metastatic SCCHN who received ≥ 3 lines of systemic 
pling was used to collect data on inpatients costs of breast cancer in 3 cities (Beijing, 
Shanghai and Chengdu) in China in 2011. 314 patients were screened into this study 
from national claimed database of urban employees. Statistics analysis and descrip-
tive analysis were used to find out direct medical costs and reimbursement rate 
of patients hospitalized with breast cancer in different treatment type. Results: 
The mean hospitalization expense of all inpatient with breast cancer was USD 2,154 
per patient (66% of the expense was covered by public payer), while drug expense 
was USD 1,197 (82% covered by public payer). The mean cost per patient was CNY 
19,554 (USD 3,154) for surgery patients (49 patients) and CNY 10,588 (USD 1,708) for 
non-surgery patients (265 patients), the mean reimbursement rate was 60% and 
70%, drug-to-total expense ratio was 41% and 69% and mean length of hospital stay 
was 20 days and 9 days for surgery patients and non-surgery patients identically. 
The overall reimbursement rate of medical services was only 46%, much lower 
comparing with reimbursement rate of drug (82%), causing even higher OOP burden 
of surgery patients who usually needs more medical services (mean expense on 
medical services per surgery patient and non surgery patient was USD 1,875 and 
USD 536). cOnclusiOns: Among women in China, breast cancer is the most com-
mon and the leading cause of death from all cancers, which brings heavy burden 
to patients and families. Surgery patients suffered higher OOP burden because of 
relatively lower reimbursement rate on medical services and longer hospital stay. 
The government needs to gradually raise the reimbursement rate and introduce 
more commercial health insurance products to cover on patient financial burden.
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Objectives: Breast cancer is the second leading cause of cancer-related deaths 
among women age < 50 years. Published studies on the health and productivity 
effects of breast cancer mortality among younger women are limited. PuRPOse: 
To assess trends in breast cancer mortality rates among young women aged 18-44 
years, estimate years of potential life lost (YPLL), and the value of productivity losses 
due to premature mortality. MethOds: Age-adjusted rates and rate ratios (RRs) 
were calculated using 1970-2012 U.S. mortality data. Changes in breast cancer mor-
tality rates over time were assessed using Joinpoint regression modeling. YPLL was 
calculated using number of cancer deaths and the remaining life expectancy at the 
age of death. Value of productivity losses was estimated using the number of deaths 
and the present value of future lifetime earnings. Results: From 1970 through 
2012, the age-adjusted breast cancer mortality rate among young women was 
12.02/100,000. Rates were higher in the Northeast (RR = 1.03; 95% CI, 1.02-1.04). The 
annual decline in breast cancer mortality rates among blacks was smaller (-0.68%) 
compared with whites (-2.02%) and all race/ethnicity (-1.77%). The total number of 
deaths associated with breast cancer was 225,866, which accounted for an estimated 
7.98 million YPLL. The estimated total productivity loss in 2008 was $5.49 billion 
and individual lifetime lost earnings were $1.10 million. cOnclusiOns: Breast 
cancer mortality among young women is associated with substantial health and 
economic burden. Considering the effect of breast cancer on women of working-age 
and the disproportionate impact on black women, more aggressive interventions 
with multiple strategies are needed to help reduce these burdens, improve survival 
and in turn reduce productivity costs associated with premature death.
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Objectives: Across Europe, clinical and economic burden of advanced non-small 
cell lung cancer (aNSCLC) remains high; regional variation and cost drivers are 
not completely understood. The Leading the Evaluation of Non-squamous and 
Squamous NSCLC (LENS) study aimed to systematically describe aNSCLC-attrib-
utable healthcare resource utilization (HCRU) and costs within aNSCLC patients 
who received ≥ 2 lines of systemic therapy. MethOds: Patients diagnosed with 
aNSCLC (Stage IIIb/IV) between 07/2009-08/2011 who initiated second-line treat-
ment (excluding clinical trial patients) were quota sampled from 153 oncology/
pulmonology practices (92% hospital-based) in France, Germany, Italy, and Spain. 
Medical charts were reviewed for patient characteristics and outcomes including 
aNSCLC-related HCRU from diagnosis through death or most recent visit (data 
abstracted in January-May 2014). Country-specific unit costs were obtained from 
national price indexes and published literature, inflated to 2014€ . Average lifetime 
costs were calculated using observed and Kaplan-Meier approaches to adjust for 
incomplete follow-up. Results: 835 patients (Non-squamous= 418, Squamous= 417; 
France= 191, Germany= 225, Italy= 220, Spain= 199; median age 65 years; 85.0% smok-
ing history; 39.8% current smokers) were observed over a mean 20.7 months (range 
2.8-57.1 months; 76.3% followed through death). 11.9%/6.1% had aNSCLC-related 
hospitalizations/ER visits, 68.3% biomarker testing, 16.8% radiotherapy, 4.2% sur-
gery, and 27.9% supplemental therapies. Estimated per-patient lifetime aNSCLC-
attributable costs were € 62,481 (France= € 54,936, Germany= € 71,508, Italy= € 41,447, 
Spain= € 65,424). Costs were driven by systemic treatment (systemic treatment 
cost= € 50,737; in squamous, € 28,107; non-squamous, € 71,060). cOnclusiOns: 
Treatment was the primary aNSCLC-related cost driver, with histology-based dif-
ferences driven by lower systemic use in squamous patients. The observed levels 
